Skip to main content
Figure 6 | BMC Medicine

Figure 6

From: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy

Figure 6

Results of clopidogrel low-response (CLR) following therapy modification including prasugrel. The left section of the figure shows the prevalence in % (numbers) of clopidogrel responder and clopidogrel low responder (CLR). In the right section are the results after therapy modification according to the therapy algorithm for CLR including prasugrel. Clopidogrel responder were treated with 75 mg daily and the high clopidogrel dose was 150 mg daily. Definite low responder were low responder to either clopidogrel high dose or prasugrel high dose.

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us